Processa Pharmaceuticals, Inc.
PCSANASDAQHealthcare● Active
$2.42
$-0.10(-3.97%)
Market Cap$5483159
P/E Ratio—
52W High$19.625
52W Low$1.76
Processa Pharmaceuticals, Inc. (PCSA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PCSA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.29
Est. -$1.00 · -29.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
PCSA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.00 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.00 | -$1.29 | -29.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$1.50 | -$18.50 | -1133.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$2.00 | -$1.75 | +12.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.23 | -$0.25 | -8.7% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.77 | -$0.30 | +61.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.92 | -$0.74 | +19.6% | — | — | — |
| ▼ Q4 FY2024 | Oct 30, 2024 | -$1.00 | -$1.03 | -3.0% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.29
EPS Est.
-$1.00
EPS Surpr.
-29.0%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$18.50
EPS Est.
-$1.50
EPS Surpr.
-1133.3%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$1.75
EPS Est.
-$2.00
EPS Surpr.
+12.5%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.23
EPS Surpr.
-8.7%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.77
EPS Surpr.
+61.0%
Revenue
—
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.74
EPS Est.
-$0.92
EPS Surpr.
+19.6%
Revenue
—
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
-$1.03
EPS Est.
-$1.00
EPS Surpr.
-3.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q3 FY2026 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q2 FY2026 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q1 FY2026 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Q4 FY2025 | $-1.25 | $-1.25 | $-1.25 | 1 |
| Q3 FY2025 | $-2.00 | $-2.00 | $-2.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -29.0% | $2.75 | $2.87 | +4.36% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -1133.3% | $3.16 | $2.33 | -26.27% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +12.5% | $8.50 | $7.90 | -7.06% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -8.7% | $5.69 | $5.78 | +1.58% |
| ▲ Q2 FY2025 | May 8, 2025 | +61.0% | $6.44 | $6.85 | +6.37% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +19.6% | $10.61 | $10.63 | +0.19% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -3.0% | $33.75 | $33.25 | -1.48% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -3.1% | $36.50 | $34.00 | -6.85% |
Q2 FY2026+4.36%
Report Date
May 7, 2026
EPS Beat/Miss
-29.0%
Price Before
$2.75
Price After
$2.87
Q1 FY2026-26.27%
Report Date
Mar 19, 2026
EPS Beat/Miss
-1133.3%
Price Before
$3.16
Price After
$2.33
Q4 FY2025-7.06%
Report Date
Nov 6, 2025
EPS Beat/Miss
+12.5%
Price Before
$8.50
Price After
$7.90
Q3 FY2025+1.58%
Report Date
Aug 7, 2025
EPS Beat/Miss
-8.7%
Price Before
$5.69
Price After
$5.78
Q2 FY2025+6.37%
Report Date
May 8, 2025
EPS Beat/Miss
+61.0%
Price Before
$6.44
Price After
$6.85
Q1 FY2025+0.19%
Report Date
Mar 20, 2025
EPS Beat/Miss
+19.6%
Price Before
$10.61
Price After
$10.63
Q4 FY2024-1.48%
Report Date
Oct 30, 2024
EPS Beat/Miss
-3.0%
Price Before
$33.75
Price After
$33.25
Q3 FY2024-6.85%
Report Date
Aug 13, 2024
EPS Beat/Miss
-3.1%
Price Before
$36.50
Price After
$34.00
Avg Beat Reaction-0.17%
Avg Miss Reaction-5.73%
Beat Rate3 / 8 quarters
Largest Move-26.27% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PCSA ends December
Processa Pharmaceuticals, Inc. (PCSA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.29 — missing the analyst consensus of $-1.00 by -29.0%. The next PCSA earnings date is expected around September 1, 2026.
Each quarter, investors track PCSA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PCSA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PCSA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PCSA earnings · 5 questionsProcessa Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PCSA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PCSA historically reports after market close (AMC).
PCSA earnings datewhen is PCSA earningsPCSA next earnings datewhen does PCSA report earningsPCSA earnings calendar
▸ Source: FMP · Processa Pharmaceuticals, Inc. SEC filings · US GAAP · Processa Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026